Janux Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-22.1%projected annual EPS growth
Analyst Coverage
16analysts covering
FY Revenue (est.)
$29.5Mnext fiscal year
FY EPS (est.)
-$1.76next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Initial Clinical Update for JANX011 Phase 1 Study | 31 Dec 2026 |
| Additional Clinical Data for JANX007 at Medical Congress | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Short-Term Investments Quarterly956.4MTarget: Maintain sufficient runway to support clinical trials through 2027+
Research and Development (R&D) Expenses Quarterly26.8MTarget: Manage within budgeted clinical development plans
General and Administrative (G&A) Expenses Quarterly11.1MTarget: Optimize administrative overhead during clinical scaling
Watch Items
- JANX007 Phase 1b Clinical Trial ProgressTrigger: Enrollment completion of taxane-naïve and combination cohortsAction: Monitor clinical updates and safety profiles for Grade 3 CRS events
- JANX011 Phase 1 Study in Healthy VolunteersTrigger: Initial clinical data release in 2H 2026Action: Evaluate safety and pharmacokinetic data to support autoimmune disease strategy
- JANX013 Clinical Development InitiationTrigger: IND clearance and first patient dosed in 2H 2026Action: Track transition of PSMA-targeted CD28 costimulatory TRACIr into clinical phase
Research as of 19 Jun 2026